Hypersensitivity reactions to quinolones

Current Pharmaceutical Design

Volumn 12, Issue 26, 2006, Pages 3313-3326

  Schmid, Daphné Anne ^a   Campi, Paolo ^b   Pichler, Werner Joseph ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Crossreactivity; Hypersensitivity; IgE mediated; Quinolones; T cell mediated

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN; CARBAMAZEPINE; CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; IMMUNOGLOBULIN E; LAMOTRIGINE; LEVOFLOXACIN; LIDOCAINE; LOMEFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPEMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULFAMETHOXAZOLE; TEMAFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; UNINDEXED DRUG;

ACUTE HEPATITIS; ACUTE PANCREATITIS; ALLERGIC VASCULITIS; ANAPHYLACTIC SHOCK; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIONEUROTIC EDEMA; ANTHRAX; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIGEN RECOGNITION; BACTERIAL PNEUMONIA; BLOOD DYSCRASIA; CELLULAR IMMUNITY; CLINICAL TRIAL; CROSS REACTION; DELAYED HYPERSENSITIVITY; DIAGNOSTIC VALUE; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ERYTHEMA; GOUT; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INTERSTITIAL NEPHRITIS; INTRACUTANEOUS TEST; ISCHEMIC COLITIS; KIDNEY DISEASE; LARYNX EDEMA; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LIVER TRANSPLANTATION; MACULOPAPULAR RASH; MENINGITIS; NONHUMAN; OBSTRUCTIVE JAUNDICE; PANCYTOPENIA; PHOTOSENSITIZATION; PHOTOTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; PUSTULOSIS; REVIEW; SERUM SICKNESS; SEXUALLY TRANSMITTED DISEASE; SKIN ALLERGY; SKIN TEST; STEVENS JOHNSON SYNDROME; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; T LYMPHOCYTE; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; URTICARIA;

DRUG HYPERSENSITIVITY; HUMANS; QUINOLONES;

EID: 33748576562     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778194033     Document Type: Review

References (205)

1. Lesher G Y, Froelich E J, Gruett M D, Bailey J H, Brundage R P. 18-Naphthyridine Derivatives. A New Class Of Chemotherapeutic Agents. J Med Pharm Chem 1962; 91: 1063-5.
2. Larouche G. Les quinolones: des années soixante à aujourd'hui. Pharmactuel 2001; 34: 40-46.
3. Hooper D C, Wolfson J S. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324: 384-94.
4. Norrby S R, Lietman P S. Safety and tolerability of fluoroquinolones. Drugs 1993; 45(Suppl 3): 59-64.
5. Bhanot S K, Singh M, Chatterjee N R. The chemical and biological aspects of fluoroquinolones: reality and dreams. Curr Pharm Des 2001; 7: 311-35.
6. Paton J H, Reeves D S. Fluoroquinolone antibiotics. Microbiology pharmacokinetics and clinical use. Drugs 1988; 36: 193-228.
7. Noble C G, Barnard F M, Maxwell A. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex. Antimicrob Agents Chemother 2003; 47: 854-62.
8. Hooper D C. Mode of action of fluoroquinolones. Drugs 1999; 58(Suppl 2): 6-10.
9. Anderson V E, Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 2001; 7: 337-53.
10. Drlica K, Zhao X. DNA gyrase topoisomerase IV and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-92.
11. Shen L L. A reply: "Do quinolones bind to DNA?" - Yes. Biochem Pharmacol 1989; 38: 2042-4.
12. Shen L L, Kohlbrenner W E, Weigl D, Baranowski J. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique nor-floxacin binding sites in enzyme-DNA complexes. J Biol Chem 1989; 264: 2973-8.
13. Shen L L, Baranowski J, Pernet A G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry 1989; 28: 3879-85.
14. Hooper D C, Wolfson J S. Mode of action of the new quinolones: new data. Eur J Clin Microbiol-Infect Dis 1991; 10: 223-31.
15. Domagala J M. Structure-activity and structure-side-eflect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706.
16. Manfredi M, Severino, M, Testi S, Macchia D, Ermini G, Pichler W J, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004; 113: 155-60.
17. Campi P, Pichler W J. Quinolone hypersensitivity. Curt Opin Allergy Clin Immunol 2003; 3: 275-81.
18. Ball P. Future of the quinolones. Semin Respir Infect 2001; 16: 215-24.
19. Blum M D, Graham D J, McCloskey C A. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994; 18: 946-50.
20. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999; 21: 407-21.
21. Allan D S, Thompson C M, Barr R M, Clark W F, Chin-Yee I H. Ciprofloxacin-associated hemolytic-uremic syndrome. Ann Pharmacother 2002; 36: 1000-2.
22. Miedouge M, Hacini J, Grimont F, Watine J. Shiga, toxin-producing Escherichia coli urinary tract infection associated with hemolytic-uremic syndrome in an adult and possible adverse effect of ofloxacin therapy. Clin Infect Dis 2000; 30: 395-6.
23. Maguire R B, Stroncek D F, Gale E, Yearlsey M. Hemolytic anemia and acute renal failure associated with temafloxacin-dependent antibodies. Am J Hematol 1994; 46: 363-6.
24. Aydogdu I, Ozerol I H, Tayfun E, Harputluoglu M. Autoimmune haemolytic anaemia and thrombocytopenia associated with ciprofloxacin. Clin Lab Haematol 1997; 19: 223.
25. Gales B J, Sulak L B. Severe thrombocytopenia associated with alatrofloxacin. Ann Pharmacother 2000; 34: 330-4.
26. Wensing J W, Vlasveld L T. [Immune thrombocytopenia attributed to norfloxacin]. Ned Tijdschr Geneeskd 1997; 141: 1660-2.
27. Teh C, McKendrick M. Ciprofloxacin-induced thrombocytopenia. J Infect 1993; 27: 213-5.
28. Mitropoulos F A, Angood P B, Rabinovici R. Trovafloxacin-associated leukopenia. Ann Pharmacother 2001; 35: 41-4.
29. Choo P W, Gantz N M. Reversible leukopenia related to ciprofloxacin therapy. South Med J 1990; 83: 597-8.
30. Lim S, Alam M G. Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia. Ren Fail 2003; 25: 647-51.
31. Ramalakshmi S, Bastacky S, Johnson J P. Levofloxacin-induced granulomatous interstitial nephritis. Am J Kidney Dis 2003; 41: E7.
32. Bennett W M, Elzinga L W. Porter G A. Tubulointerstitial disease and toxic nephropathy. Pathogenesis of Renal Disease Chapter 29 1430-1441.
33. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60: 804-17.
34. Helmink R, Benediktsson H. Ciprofloxacin-induced allergic interstitial nephritis. Nephron 1990; 55: 432-3.
35. Oliveira H S, Goncalo M, Figueiredo A C. Photosensitivity to lomefloxacin. A clinical and photobiological study. Photodermatol Photoimmunol Photomed 2000; 16: 116-20.
36. Tokura Y, Seo N, Ohshima A, Yagi H, Furukawa F, Takigawa M. Lymphocyte stimulation test with drug-photomodified cells in patients with quinolone photosensitivity. J Dermatol Sci 1999; 21: 34-41.
37. Kawabe Y, Mizuno N, Sakakibara S. Photoallergic reaction caused by enoxacin. Photodermatol 1989; 6: 57-9.
38. Kurumaji Y, Shono M. Scarified photopatch testing in lomefloxacin photosensitivity. Contact Dermatitis 1992; 26: 5-10.
39. Lucena M I, Andrade R J, Rodrigo L, Salmeron J, Alvarez A, Lopez-Garrido M J, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000; 30: 400-1.
40. Corey A D T. Dillaha JA. Trovofloxacin-Induced Acute Hepatitis. Clinical Infectious Diseases 2000; 30: 400.
41. Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S. Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch 2004; 444: 87-9.
42. Lucena M I, Andrade R J, Sanchez-Martinez H, Perez-Serrano J M, Gomez-Outes A. Norfloxacin-induced cholestatic jaundice. Am J Gastroenterol 1998; 93: 2309-11.
43. Labowitz J K, Silverman W B. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci 1997; 42: 192-4.
44. Sherman O, Beizer J L. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother 1994; 28: 1162-4.
45. Hallgren J, Tengvall-Linder M, Persson M, Wahlgren C F. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol 2003; 49: S267-9.
46. Uppal R, Jhaj R, Malhotra, S. Adverse drug reactions to fluoroquinolones at a tertiary care hospital in northern India. J Assoc Physicians India 1998; 46: 946-7.
47. Jongen-Lavrencic M, Schneeberger P M, van der Hoeven J G. Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. Infection 2003; 31: 428-9.
48. Yerasi A B, Oertel M D. Ciprofloxacin-induced toxic epidermal necrolysis. Ann Pharmacother 1996; 30: 297.
49. Sakellariou G, Koukoudis P, Karpouzas J, Alexopoulos E, Papadopoulou D, Chrisomalis F, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 1991; 14: 634-8.
50. Lery N, Zemni M, Carraut J, Loupi E, Vedrinne J. [Death caused by Lyell's syndrome after prescription of pipemidic acid (Pipram): imputability and medico-legal problems]. Acta Med Leg Soc (Liege) 1985; 35: 55-61.
51. Roujeau J C, Kelly J P, Naldi L, Rzany B, Stern R S, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
52. Nettis E, Giordano D, Pierluigi T, Ferrannini A, Tursi A. Erythema multiforme-like rash in a patient sensitive to ofloxacin. Acta Derm Venereol 2002; 82: 395-6.
53. Bircher A J, Rutishauser M. Oral "desensitization" of maculopapular exanthema from ciprofloxacin. Allergy 1997; 52: 1246-8.
54. Cheung O, Chopra K, Yu T, Nalesnik M A, Amin S, Shakil A O. Gatifloxacin-induced hepatotoxicity and acute pancreatitis. Ann Intern Med 2004; 140: 73-4.
55. Drabo Y J, Niakara A, Ouedraogo H. Acute pancreatitis secondary to administration or norfloxacin. Ann Fr Anesth Reanim 2002; 21: 68-9.
56. Mennecier D, Thiolet C, Bredin C, Potier V, Vergeau B, Farret O. Acute pancreatitis after treatment by levofloxacin and methylpred-nisolone. Gastroenterol Clin Biol 2001; 25: 921-2.
57. Slama T G. Serum sickness-tike illness associated with ciprofloxacin. Antimicrob Agents Chemother 1990; 34: 904-5.
58. Guharoy S R. Serum sickness secondary to ciprofloxacin use. Vet Hum Toxicol 1994; 36: 540-1.
59. de la Torre Lima F J, Rubio Rubio J M, Garrachon Vallo F, Pichardo Carballo J J, Sanchez Lopez M P, Zamora Madaria E. Angio-immunoblastic lymphadenopathy. Apropos a case with unusual clinical manifestations and evolution to T-cell lymphoma. An Med Interna 1994; 11: 442-4.
60. Knoops L, van den Neste E, Hamels J, Theate I, Mineur P. Angio-immunoblastic lymphadenopathy following ciprofloxacin administration. Acta Clin Belg 2002; 57: 71-3.
61. Shelley E D, Shelley W B. The subcorneal pustular drug eruption: an example induced by norfloxacin. Cutis 1988; 42: 24-7.
62. Tsuda S, Kato K, Karashima T, Inou Y, Sasai Y. Toxic pustuloderma induced by ofloxacin. Acta Derm Venereol 1993; 73: 382-4.
63. Asperilla M O, Smego, R A. Jr. Eosinophilic meningitis associated with ciprofloxacin. Am J Med 1989; 87: 589-90.
64. Valdivieso R P J. Losada E Subiza J Armentia A Zapata C. Severe anaphylactoid reaction to nalidixic acid. Allergy 1988; 43: 71-3.
65. Davis H, McGoodwin E, Reed T G. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989; 111: 1041-3.
66. Deamer RL P J. Loman GJ. Hypersensitivity and anaphylactoid reaction to ciprofloxacin. Ann Pharmacother 1992; 26: 1081-4.
67. Soetikno RM J J. Carey JT. Ciprofloxacin-induced anaphylactoid reaction in a patient with AIDS. Ann Pharmacother 1993; 27: 1404.
68. Alonso M D, Martin J A, Quirce S, Davila I, Lezaun A, Sanchez Cano M. Fixed eruption caused by ciprofloxacin with cross-sensitivity to norfloxacin. Allergy 1993; 48: 296-7.
69. Lozano Ayllon M, Gomez Martinez M, Mosquera M R, Laguna Martinez J J, Orta Martiartu M, Fernandez de Miguel C. Fixed eruption caused by ciprofloxacin without cross-sensitivity to norfloxacin. Allergy 1995; 50: 598-9.
70. Davila I, Diez M L, Quirce S, Fraj J, De La Hoz B, Lazaro M. Cross-reactivity between quinolones. Report of three cases. Allergy 1993; 48: 388-90.
71. Colas C P J. Zapata C Dominguez A Gimeno A Duce F. Quinolones hypersensitivity: clinical and immunological aspects. J Allergy Clin Immunol 1993; 91: 365.
72. Kurata M, Kasuga, Y, Nanba E, Nakamura H, Asano T, Haruta K. Flush induced by fluoroquinolones in canine skin. Inflamm Res 1995; 44: 461-5.
73. Arboit F B J. De Blay F, et al. L'allergie aux quinolones - à propos de huit observations. Rev Fr Allergol 1997; 37: 15-19.
74. Gea-Banacloche J C, Metcalfe D D. Ciprofloxacin desensitization. J Allergy Clin Immunol 1996; 97: 1426-7.
75. Seropian E. Imminent shock; a useful diagnosis in drug pathology. Allergol Immunopathol (Madr) 1976; 4: 435-40.
76. Fernandez-Rivas M. Fixed drug eruption (FDE) caused by norfloxacin. Allergy 1997; 52: 477-8.
77. Reano M, Vives R, Rodriguez J, Daroca P, Canto G, Fernandez J. Ciprofloxacin-induced vasculitis. Allergy 1997; 52: 599-600.
78. Baldo B A, Harle D G. Drug allergenic determinants. Monogr Allergy 1990; 28: 11-51.
79. Harle D G, Baldo B A, Wells J V. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol 1988; 25: 1347-54.
80. Smal M A, Baldo B A, Harle D G. Drugs as allergens. The molecular basis of IgE binding to trimethoprim. Allergy 1988; 43: 184-91.
81. Janeway CA T P. Walport M Shlochik M. Immunobiology: the immune system in health and disease. Garland Publishing 2001.
82. Kehren J, Desvignes C, Krasteva M, Ducluzeau M T, Assossou O, Horand F, et al. Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity. J Exp Med 1999; 189: 779-86.
83. Wang B, Feliciani C, Freed I, Cai Q, Sauder D N. Insights into molecular mechanisms of contact hypersensitivity gained from gene knockout studies. J Leukoc Biol 2001; 70: 185-91.
84. Houwerzijl J, De Gast G C, Nater J P, Esselink M T, Nieweg H O. Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. Clin Exp Immunol 1977; 29: 272-7.
85. Matson J R, Krous H F, Blackstock R. Diphenylhydantoin-induced hypersensitivity reaction with interstitial nephritis. Hum Pathol 1985; 16: 94-7.
86. Meys E, Devogelaer J P, Geubel A, Rahier J, Nagant de Deuxchaisnes C. Fever hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity. J Rheumatol 1992; 19: 807-9.
87. Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29: 254-7.
88. Rodriguez-Morales A, Llamazares A A, Benito R P, Cocera C M. Fixed drug eruption from quinolones with a positive lesional patch test to ciprofloxacin. Contact Dermatitis 2001; 44: 255.
89. Ronnau A C, Sachs B, von Schmiedeberg S, Hunzelmann N, Ruzicka T, Gleichmann E, et al. Cutaneous adverse reaction to ciprofloxacin: demonstration of specific lymphocyte proliferation and cross-reactivity to ofloxacin in vitro. Acta Derm Venereol 1997; 77: p285-8.
90. Kuechler P C, Britschgi M, Schmid S, Hari Y, Grabscheid B, Pichler W J. Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 2004; 59: 613-22.
91. Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118: 728-33.
92. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225-30.
93. Subat-Dezulovic M, Slavic I, Rozmanic V, Persic M, Medjimurec B, Scukanec-Spoljar M. Drug-induced acute tubulointerstitial nephritis: a case with elevated urinary cadmium. Pediatr Nephrol 2002; 17: 382-5.
94. Reece R J, Nicholls A J. Ciprofloxacin-induced acute interstitial nephritis. Nephrol Dial Transplant 1996; 11: 393.
95. Allon M, Lopez E J, Min K W. Acute renal failure due to ciprofloxacin. Arch Intern Med 1990; 150: 2187-9.
96. Arvieux C, Charasse C, Guilhem L Rivalan J, Le Pogamp P, Ramee M P. Acute renal insufficiency caused by tubulo-interstitial nephropathy after treatment with ciprofloxacin. Ann Med Interne (Paris) 1991; 142: 554-6.
97. Bailey J R, Trott S A, Philbrick J T. Ciprofloxacin-induced acute interstitial nephritis. Am J Nephrol 1992; 12: 271-3.
98. Bald M, Ratjen F, Nikolaizik W, Wingen A M. Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. Pediatr Infect Dis J 2001; 20: 320-1.
99. Boelaert J, de Jaegere P P, Daneels R, Schurgers M, Gordts B, van Landuyt H W. Case report of renal failure during norfloxacin therapy. Clin Nephrol 1986; 25: 272.
100. Connor J P, Curry J M, Selby T L, Perlmutter A D. Acute renal failure secondary to ciprofloxacin use. J Urol 1994; 151: 975-6.
101. Espiritu J, Walton T. Acute renal failure due to ofloxacin. W V Med J 1995; 91: 16.
102. Gauffre A, Mircheva J, Glotz D, Fillastre J P, Simon P, Beaune P H, et al. Autoantibodies against a kidney - liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis. Nephrol Dial Transplant 1997; 12: 1961-2.
103. Godin M, Ducastelle T, Bercoff E, Dubois D, Fillastre J P, Bourreille J. Renal failure and quinolone. Nephron 1984; 37: 70-2.
104. Gonski P N. Ciprofloxacin-induced renal failure in an elderly patient. Med J Aust 1991; 154: 638-9.
105. Hadimeri H, Almroth G, Cederbrant Y, Enestrom S, Hultman P, Lindell A. Allergic nephropathy associated with norfloxacin and ciprofloxacin therapy. Report of two cases and review of the literature. Scand J Urol Nephrol 1997; 31: 481-5.
106. Hootkins R, Fenves A Z, Stephens M K. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32: 75-8.
107. Lee C W, Fialkow R Z, Van Wyck D. Adverse effects associated with the newer fluoroquinolones. Am J Kidney Dis 1989; 13: 510-1.
108. Lien Y H, Hansen R, Kern W F, Bangert J, Nagle R B, Ko M, et al. Ciprofloxacin-induced granulomatous interstitial nephritis and localized elastolysis. Am J Kidney Dis 1993; 22: 598-602.
109. Lo W K, Rolston K V, Rubenstein E B, Bodey G P. Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med 1993; 153: 1258-62.
110. Lucena M I, Marquez M, Velasco J L, Andrade R J. Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome. Arch Intern Med 1995; 155: 114-5.
111. Murray K M, Wilson M G. Suspected ciprofloxacin-induced interstitial nephritis. Dicp 1990; 24: 379-80.
112. Nakamura M, Ohishi A, Aosaki N, Hamaguchi K. Norfloxacin-induced acute interstitial nephritis. Nephron 2000; 86: 204-5.
113. Raja N, Miller W E, McMillan R, Mason J R. Ciprofloxacin-associated acute renal failure in patients undergoing high-dose chemotherapy and autologous stem cell rescue. Bone Marrow Transplant 1998; 21: 1283-4.
114. Rastogi S, Atkinson J L, McCarthy J T. Allergic nephropathy associated with ciprofloxacin. Mayo Clin Proc 1990; 65: 987-9.
115. Rippelmeyer D J, Synhavsky A. Ciprofloxacin and allergic interstitial nephritis. Ann Intern Med 1988; 109: 170.
116. Rosado L J, Siskind M S, Copeland J G. Acute interstitial nephritis in a cardiac transplant recipient receiving ciprofloxacin. J Thorac Cardiovasc Surg 1994; 107: 1364; author reply 1364-6.
117. Rossi E, Silvestri M G, Manari A, Savazzi G, Migone L. Acute renal failure and piromidic acid. Nephron 1982; 32: 80-2.
118. Shih D J, Korbet S M, Rydel J J, Schwartz M M. Renal vasculitis associated with ciprofloxacin. Am J Kidney Dis 1995; 26: 516-9.
119. Ying L S, Johnson C A. Ciprofloxacin-induced interstitial nephritis. Clin Pharm. 1989; 8: 518-21.
120. Grassmick B K, Lehr V T, Sundareson A S. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992; 26: 636-9.
121. Gonzalez Carro P, Huidobro M L, Zabala A P, Vicente E M. Fatal subfulminant hepatic failure with ofloxacin. Am J Gastroenterol 2000; 95: 1606.
122. Coleman C I, Spencer J V, Chung J O, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002; 36: 1162-7.
123. Spahr L, Rubbia-Brandt L, Marinescu O, Armenian B, Hadengue A. Acute fatal hepatitis related to levofloxacin. J Hepatol 2001; 35: 308-9.
124. Amitrano L, Gigliotti T, Guardascione M A, Ascione A. Acute cholestatic liver injury induced by enoxacin. J Hepatol 1993; 18: 139-40.
125. Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol 2002; 37: 696-9.
126. Bjornsson E, Olsson R, Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. Am J Gastroenterol 2000; 95: 3662-4.
127. Blum A. Ofloxazin-induced acute severe hepatitis. South Med J 1991; 84: 1158.
128. Chen H J, Bloch K J, Maclean J A. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000; 342: 359-60.
129. Contreras M A, Luna R, Mulero J, Andreu J L. Severe ciprofloxacin-induced acute hepatitis. Eur J Clin Microbiol Infect Dis 2001; 20: 434-5.
130. Hautekeete M L, Kockx M M, Naegels S, Holvoet J K, Hubens H, Kloppel G. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol 1995; 23: 759-60.
131. Henann N E, Zambie M F. Gatifloxacin-associated acute hepatitis. Pharmacotherapy 2001; 21: 1579-82.
132. Hofer T, Becker E W, Weigand K, Berg P A. Demonstration of sensitized lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis. J Hepatol 1992; 15: 262-3.
133. Jones S F, Smith R H. Quinolones may induce hepatitis. BMJ 1997; 314: 869.
134. Karim A, Ahmed S, Rossoff L J, Siddiqui R K, Steinberg H N. Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis 2001; 33: 2088-90.
135. Lazarczyk D A, Goldstein N S, Gordon S C. Trovafloxacin hepatotoxicity. Dig Dis Sci 2001; 46: 925-6.
136. Romero-Gomez M, Suarez Garcia E, Fernandez M C. Norfloxacin-induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis. Am J Gastroenterol 1999; 94: 2324-5.
137. Soto S, Lopez-Roses L, Avila S, Lancho A, Gonzalez A, Santos E, Urraca B. Moxifloxacin-induced acute liver injury. Am J Gastroenterol 2002; 97: 1853-4.
138. Villeneuve J P, Davies C, Cote J. Suspected ciprofloxacin-induced hepatotoxicity. Ann Pharmacother 1995; 29: 257-9.
139. Tsutsui H, Terano Y, Sakagami C, Hasegawa I, Mizoguchi Y, Morisawa S. Drug-specific T cells derived from patients with drug-induced allergic hepatitis. J Immunol 1992; 149: 706-16.
140. Roujeau J, Bioulac-Sage P, Bourseau C. Acute generalized exan-thematous pustulosis: Analysis of 63 cases. Arch. Dermatol 1991; 127: 1333-1338.
141. Britschgi M, Steiner U C, Schmid S, Depta J P, Senti G, Bircher A, et al. T-cell involvement in drug-induced acute generalized exan-thematous pustulosis. J Clin Invest 2001; 107: 1433-41.
142. Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni M P, Schnyder B, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31: 1398-408.
143. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen L R, Pichler W J. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30: 847-855.
144. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen L R, Pichler W J. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106: 1171-6.
145. Osawa J, Kitamura K, Saito S, Ikezawa Z, Nakajima H. Immuno-histochemical study of graft-versus-host reaction (GVHR)-type drug eruptions. J Dermatol 1994; 21: 25-30.
146. Correia O, Delgado L, Ramos J P, Resende C, Torrinha J A. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129: 466-8.
147. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263-6
148. Gaspard I, Guinnepain M T, Laurent J, Bachot N, Kerdine S, Bertoglio J, et al. I1-4 and IFN-gamma mRNA induction in human peripheral lymphocytes specific for beta-lactam antibiotics in immediate or delayed hypersensitivity reactions. J Clin Immunol 2000; 20: 107-16.
149. Orentas R J, Hildreth J E, Obah E, Polydefkis M, Smith G E, Clements M L, et al. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990; 248: 1234-1237.
150. Pichler W J. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-93.
151. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61: 643-656.
152. Weltzien H U, Moulon C, Martin S, Padovan E, Hartmann U, Kohler J. T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 1996; 107: 141-51.
153. Park B K, Pirmohamed M, Kitteringham N R. Role of drug disposition in drug hypersensitivity: A chemical molecular and clinical perspective. Chem Res Toxicol 1998; 11: 969-987.
154. Griem P, Wulferink M, Sachs B, Gonzalez J B, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19: 133-41.
155. Brander C, Mauri-Hellweg D, Bettens F, Rolli H, Goldman M, Pichler W J. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995; 155: 2670-8.
156. Padovan E, Bauer T, Tongio M M, Kalbacher H, Weltzien H U. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol 1997; 27: 1303-7.
157. Padovan E, Mauri-Hellweg D, Pichler W J, Weltzien H U. T cell recognition of penicillin G: structural features determining antigenic specificity. Eur J Immunol 1996; 26: 42-8.
158. Schneider C H, de Weck A L. Chemical aspects of penicillin allergy. The direct penicilloylation of epsilon-amino groups by penicillin at pH 7.4. Helv Chim Acta 1966; 49: 1695-706.
159. Cribb A E, Spielberg S P. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522-526.
160. Reilly T P, Lash L H, Doll M A, Hein D W, Woster P M, Svensson C G, A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114: 1164-1173.
161. Hertl M, Jugert F, Merk H F. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995; 132: 215-20.
162. Naisbitt D J, Gordon S F, Pirmohamed M, Burkhart C, Cribb A E, Pichler W J, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001; 133: 295-305.
163. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt D J, Pirmohamed M, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000; 164: 6647-6654.
164. Naisbitt D J, Gordon S F, Pirmohamed M, Park B K. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23: 483-507.
165. Burkhart C, von Greyerz S, Depta J P, Naisbitt D J, Britschgi M, Park K B, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells [In Process Citation]. Br J Pharmacol 2001; 132: 623-630.
166. Zanni M P, von Greyerz S, Hari Y, Schnyder B, Pichler W J. Recognition of local anesthetics by alphabeta+ T cells. J Invest Dermatol 1999; 112: 197-204.
167. Mauri-Hellweg D, Zanni M, Frei E, Bettens F, Brander C, Mauri D, et al. Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. J Immunol 1996; 157: 1071-109.
168. Zanni M P, von Greyerz S, Schnyder B, Brander K A, Frutig K, Hari Y, et al. HLA-restricted processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998; 102: p1591-8.
169. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, Pichler W J. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998; 28: 1412-7.
170. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-15.
171. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler W J. Direct MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100: 136-41.
172. Zanni M P, von Greyerz S, Schnyder B, Wendland T, Pichler W J. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific αβ+ T cell clones. Int. Immunol 1998; 10: 507-515.
173. Naisbitt D J, Farrell J, Wong G, Depta J P, Dodd C C, Hopkins J E, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111: 1393-403.
174. Naisbitt D J, Britschgi M, Wong G, Farrell J, Depta J P, Chadwick D W, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity phenotype and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63: 732-41.
175. Sieben S, Kawakubo Y, Al Masaoudi T, Merk H F, Blomeke B. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J Allergy Clin Immunol 2002; 109: 1005-11.
176. Christiansen C, Pichler W J, Skotland T. Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur Radiol 2000; 10: 1965-75.
177. Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, et al. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol 2005; 115: 179-85.
178. von Greyerz S, Bultemann G, Schnyder K, Burkhart C, Lotti B, Hari Y, et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol 2001; 13: 877-85.
179. Outman W R, Nightingale C H. Metabolism and the fluoroquinolones. Am J Med 1989; 87: 37S-42S.
180. Stass H. Metabolism and Excretion of Moxifloxacin. Drugs 1999; 58: 231-232.
181. Borner K, Lode H. [Biotransformation of selected gyrase inhibitors]. Infection 1986; 14(Suppl 1): S54-9.
182. Pichler W J, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-20.
183. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler W J. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides phenytoin and carbamazepine. J Immunol 1995; 155: 462-472.
184. Zanni M P, Mauri-Hellweg D, Brander C, Wendland T, Schnyder B, Frei E, et al. Characterization of lidocaine-specific T cells. J Immunol 1997; 158: 1139-1148.
185. Correia O, Delgado L, Barros M A. Bullous photodermatosis after lomefloxacin. Arch Dermatol 1994; 130: 808-9.
186. Kimura M, Kawada A. Photosensitivity induced by lomefloxacin with cross-photosensitivity to ciprofloxacin and fleroxacin. Contact Dermatitis 1998; 38: 180.
187. Drago F, Arditi M R, Rebora A. Henoch-Schonlein purpura induced by fluoroquinolones. Br J Dermatol 1994; 131: 448.
188. Kawada A, Hiruma M, Morimoto K, Ishibashi A, Banba H. Fixed drug eruption induced by ciprofloxacin followed by ofloxacin. Contact Dermatitis 1994; 31: 182-3.
189. Shear N. Factive (gemifloxacin). FDA Advisory Committee Meeting March 4 2003; www.fda.gov/ohrms/dockets/ac/03/slides/ 3931S1_04_LFLife%20Sciences-Factive.pd.
190. Depta, J P, Pichler W J. Cross-reactivity with drugs at the T cell level. Curr Opin Allergy Clin Immunol 2003; 3: 261-7.
191. Depta J P, Altznauer F, Gamerdinger K, Burkhart C, Weltzien H U, Pichler W J. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J Allergy Clin Immunol 2004; 113: 519-527.
192. Baldo B A, Pham N H. Immunoglobulin E binding determinants on beta-lactam drugs. Curr Opin Allergy Clin Immunol 2002; 2: 297-300.
193. Bugelski P J. Genetic aspects of immune-mediated adverse drug effects. Nat Rev Drug Discov 2005; 4: 59-69.
194. Chung W H, Hung S I, Hong H S, Hsih M S, Yang L C, Ho H C, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
195. Hung S I, Chung W H, Liou L B, Chu C C, Lin M, Huang H P, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-9.
196. Mallal S, Nolan D, Witt C, Masel G, Martin A M, Moore C, et al. Association between presence of HLA-B*5701 HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
197. + T cell clones J Immunol 1999; 162: 595-602.
198. Pichler W J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301-5.
199. Beermann D. Metabolism of ciprofloxacin in man. Current Clinical Practice Series 1985; 34: 141-146.
200. Engler O B, Strasser I, Naisbitt D J, Cerny A, Pichler W J. A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 2004; 197: 47-56.
201. Vollmer J, Weltzien H U, Dormoy A, Pistoor F, Mouton C. Functional expression and analysis of a human HLA-DQ restricted nickel-reactive T cell receptor in mouse hybridoma cells. Journal of Investigative Dermatology 1999; 113: 175-81.
202. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 2006; 36(1): 59-69.
203. Jacobs MR. Fluoroquinolones as chemotherapeutics against myco-bacterial infections. Curr Pharm Des 2004; 10(26): 3213-20.
204. Luskova P, Draber P. Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. Curr Pharm Des 2004; 10(15): 1727-37.
205. Mitsumori S. Recent progress in work on PGD2 antagonists for drugs targeting allergic diseases. Curr Pharm Des 2004; 10(28): 3533-8.